Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Zhejiang Genfleet Therapeutics Co. Ltd. has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners and 4 distinct art units, showing a broad spread of review across the patent office's specialized groups. This distribution indicates that each pending matter is being handled by a different examiner, requiring a tailored approach for every case.
The busiest examiner for the portfolio is KWON, YONG SOK. This examiner is currently handling 1 pending office action. Given that there are 5 distinct examiners for the 5 pending office actions, no single examiner holds a majority of the cases. This one-to-one ratio between actions and examiners suggests that the company's prosecution strategy must account for five different sets of examiner preferences and styles.
With 4 distinct art units involved, the portfolio covers a variety of technical niches within the Biotechnology & Pharmaceuticals sector. The 1 pending office action assigned to the busiest examiner, KWON, YONG SOK, reflects the decentralized nature of the current prosecution pipeline. Practitioners should be prepared to manage multiple parallel tracks of communication across the 4 distinct art units currently engaged.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 75.2% | +34.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568791 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | VALENROD, YEVGENY | 11d overdue |
| 18723594 | POLYMORPH OF KRAS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | KWON, YONG SOK | — |
| 18558139 | PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHTERENGARTS, SAMANTHA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18381121 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | COLEMAN, BRENDA LIBBY | 50d overdue |
| 18568791 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | VALENROD, YEVGENY | 11d overdue |
| 18282254 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HEASLEY, MEGHAN CHRISTINE | 56d |
| 18723594 | POLYMORPH OF KRAS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | KWON, YONG SOK | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1623 | 1 |
| 1624 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18723594 | POLYMORPH OF KRAS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | KWON, YONG SOK | — | §102§103§112DP | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18568791 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | VALENROD, YEVGENY | 1628 | §102§112Other | Non-Final OA | 11d overdue | Pending | Dec 08, 2023 |
| 18558139 | PYRIDINO-OR PYRIMIDO-CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHTERENGARTS, SAMANTHA L | 1623 | §102§112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18381121 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | COLEMAN, BRENDA LIBBY | 1624 | §112Other | Final Rejection | 50d overdue | Pending | Oct 17, 2023 |
| 18282254 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HEASLEY, MEGHAN CHRISTINE | 1626 | §102 | Non-Final OA | 56d | Pending | Sep 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial